(ENOV) Enovis - Ratings and Ratios
Braces, Implants, Therapy Devices, Surgical Tools
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 55.0% |
| Value at Risk 5%th | 82.5% |
| Relative Tail Risk | -8.87% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.04 |
| Alpha | -62.68 |
| CAGR/Max DD | -0.35 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.469 |
| Beta | 1.398 |
| Beta Downside | 1.321 |
| Drawdowns 3y | |
|---|---|
| Max DD | 60.95% |
| Mean DD | 28.15% |
| Median DD | 27.74% |
Description: ENOV Enovis November 12, 2025
Enovis Corp. (NYSE: ENOV) is a U.S.-based medical-technology firm that develops clinically differentiated orthopedic and reconstructive solutions for both domestic and international markets. The company operates through two primary segments: Prevention & Recovery, which supplies bracing, therapy devices, bone-growth stimulators, compression garments and related physical-therapy products; and Reconstructive, which designs and sells surgical implants for the hip, knee, shoulder, elbow, foot, ankle and finger, as well as productivity tools used in joint-replacement procedures.
In FY 2023 Enovis reported revenue of roughly **$1.6 billion**, up about **8 % year-over-year**, with an adjusted operating margin near **9 %**-a modest improvement driven by higher implant volumes and the integration of the DJO brand acquired in 2022. The company’s cash conversion cycle has shortened to approximately **45 days**, reflecting more efficient inventory and receivables management after shifting a larger share of sales to direct-to-hospital channels.
Key macro drivers for Enovis include the **aging U.S. population**, which is projected to increase demand for joint-replacement surgeries by an estimated **4–5 % annually** through 2030, and **ongoing Medicare reimbursement reforms** that pressure pricing but also create opportunities for value-based product bundles. Additionally, the broader **health-care equipment sector** benefits from supply-chain resilience improvements and a shift toward outpatient orthopedic procedures, which favor lighter, modular implant systems that Enovis markets.
For a deeper quantitative dive, you might explore ValueRay’s platform to see the latest consensus estimates and risk metrics for ENOV.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-1.37b TTM) > 0 and > 6% of Revenue (6% = 134.0m TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA 1.63pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 31.55% (prev 33.61%; Δ -2.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 217.1m > Net Income -1.37b (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.22 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (56.8m) change vs 12m ago 2.02% (target <= -2.0% for YES) |
| Gross Margin 58.36% (prev 56.83%; Δ 1.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 44.74% (prev 36.07%; Δ 8.67pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -26.36 (EBITDA TTM -989.6m / Interest Expense TTM 48.4m) >= 6 (WARN >= 3) |
Altman Z'' -1.81
| (A) 0.16 = (Total Current Assets 1.28b - Total Current Liabilities 575.4m) / Total Assets 4.43b |
| (B) -0.21 = Retained Earnings (Balance) -946.9m / Total Assets 4.43b |
| (C) -0.26 = EBIT TTM -1.28b / Avg Total Assets 4.99b |
| (D) -0.42 = Book Value of Equity -1.02b / Total Liabilities 2.41b |
| Total Rating: -1.81 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 33.96
| 1. Piotroski 3.50pt |
| 2. FCF Yield 0.72% |
| 3. FCF Margin 1.02% |
| 4. Debt/Equity 0.71 |
| 5. Debt/Ebitda -1.42 |
| 6. ROIC - WACC (= -40.46)% |
| 7. RoE -55.92% |
| 8. Rev. Trend 21.44% |
| 9. EPS Trend -30.41% |
What is the price of ENOV shares?
Over the past week, the price has changed by -8.86%, over one month by -11.57%, over three months by -14.78% and over the past year by -43.58%.
Is ENOV a buy, sell or hold?
- Strong Buy: 7
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ENOV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 48.1 | 79.8% |
| Analysts Target Price | 48.1 | 79.8% |
| ValueRay Target Price | 20.7 | -22.6% |
ENOV Fundamental Data Overview November 26, 2025
P/E Forward = 8.3126
P/S = 0.7795
P/B = 0.8377
P/EG = 1.8989
Beta = 1.645
Revenue TTM = 2.23b USD
EBIT TTM = -1.28b USD
EBITDA TTM = -989.6m USD
Long Term Debt = 1.34b USD (from longTermDebt, last quarter)
Short Term Debt = 44.0m USD (from shortTermDebt, last quarter)
Debt = 1.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.41b USD (from netDebt column, last quarter)
Enterprise Value = 3.15b USD (1.74b + Debt 1.44b - CCE 33.6m)
Interest Coverage Ratio = -26.36 (Ebit TTM -1.28b / Interest Expense TTM 48.4m)
FCF Yield = 0.72% (FCF TTM 22.8m / Enterprise Value 3.15b)
FCF Margin = 1.02% (FCF TTM 22.8m / Revenue TTM 2.23b)
Net Margin = -61.22% (Net Income TTM -1.37b / Revenue TTM 2.23b)
Gross Margin = 58.36% ((Revenue TTM 2.23b - Cost of Revenue TTM 929.9m) / Revenue TTM)
Gross Margin QoQ = 59.92% (prev 59.29%)
Tobins Q-Ratio = 0.71 (Enterprise Value 3.15b / Total Assets 4.43b)
Interest Expense / Debt = 1.45% (Interest Expense 20.8m / Debt 1.44b)
Taxrate = -0.71% (negative due to tax credits) (4.00m / -566.9m)
NOPAT = -1.28b (EBIT -1.28b * (1 - -0.71%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 2.22 (Total Current Assets 1.28b / Total Current Liabilities 575.4m)
Debt / Equity = 0.71 (Debt 1.44b / totalStockholderEquity, last quarter 2.02b)
Debt / EBITDA = -1.42 (negative EBITDA) (Net Debt 1.41b / EBITDA -989.6m)
Debt / FCF = 61.83 (Net Debt 1.41b / FCF TTM 22.8m)
Total Stockholder Equity = 2.44b (last 4 quarters mean from totalStockholderEquity)
RoA = -30.84% (Net Income -1.37b / Total Assets 4.43b)
RoE = -55.92% (Net Income TTM -1.37b / Total Stockholder Equity 2.44b)
RoCE = -33.70% (EBIT -1.28b / Capital Employed (Equity 2.44b + L.T.Debt 1.34b))
RoIC = -33.69% (negative operating profit) (NOPAT -1.28b / Invested Capital 3.81b)
WACC = 6.77% (E(1.74b)/V(3.18b) * Re(11.17%) + D(1.44b)/V(3.18b) * Rd(1.45%) * (1-Tc(-0.01)))
Discount Rate = 11.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.99%
[DCF Debug] Terminal Value 57.80% ; FCFE base≈22.8m ; Y1≈14.9m ; Y5≈6.84m
Fair Price DCF = 1.54 (DCF Value 87.8m / Shares Outstanding 57.2m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -30.41 | EPS CAGR: -20.47% | SUE: 0.20 | # QB: 0
Revenue Correlation: 21.44 | Revenue CAGR: -15.30% | SUE: 2.01 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.77 | Chg30d=-0.044 | Revisions Net=-5 | Analysts=7
EPS next Year (2026-12-31): EPS=3.44 | Chg30d=-0.066 | Revisions Net=-4 | Growth EPS=+8.1% | Growth Revenue=+4.6%
Additional Sources for ENOV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle